New Zealand markets close in 52 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
68.49+5.34 (+8.46%)
At close: 04:00PM EDT
68.60 +0.11 (+0.16%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close63.15
Bid68.45 x 300
Ask68.51 x 500
Day's range64.86 - 69.47
52-week range62.07 - 87.87
Avg. volume7,181,866
Market cap85.328B
Beta (5Y monthly)0.22
PE ratio (TTM)190.25
Earnings dateN/A
Forward dividend & yield3.08 (4.50%)
Ex-dividend date14 Jun 2024
1y target estN/A
  • Yahoo Finance Video

    Housing trends, HPE CEO on Nvidia partnership: Market Domination

    There's never enough time in the day to trade, as Market Domination Hosts Julie Hyman and Josh Lipton walk investors through the final trading hour of Thursday, June 20. They cover the top trending stocks and market movements ahead of the closing bell. Hewlett Packard Enterprise (HPE) CEO Antonio Neri discusses HPE's new partnership with Nvidia (NVDA) on its line of "Nvidia AI Computing by HPE" product offerings. National Association of Home Builders (NAHB) CEO Jim Tobin stops into the studio to tackle some of the biggest challenges the US housing market is currently facing. Yahoo Finance's top trending stock tickers this hour include Gilead Sciences (GILD), commercial-grade EV maker Nikola (NKLA), and Advanced Micro Devices (AMD). This post was written by Luke Carberry Mogan.

  • Yahoo Finance Video

    Gilead Sciences stock jumps on HIV treatment trial success

    Shares of Gilead Sciences (GILD) are rising higher on Thursday as the biopharma company revealed 100% efficacy results for its HIV treatment trial, claiming it's the first Phase 3 HIV prevention trial ever to show zero Infections. Market Domination Anchors Josh Lipton and Julie Hyman break down the latest development for Gilead Sciences and what it could mean for the company moving forward For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino


    Gilead’s Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed.

    There were zero HIV cases among the 2,124 test subjects who received the antiviral injection called lenacapavir.